(MedPage Today) — Note that some links may require registration or subscription.
The Infectious Diseases Society of America (IDSA) changed course on tocilizumab (Actemra), and now conditionally recommends the IL-6 blocker on top of standard care…
Source link
Comments are closed, but trackbacks and pingbacks are open.